Drugs / BMS-986368
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07700329 | Jan → Feb 2027 expected | — | Celgene Corporation | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06411730 | May → Oct 2024 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06170723 | Mar → May 2024 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06227975 | Feb → Apr 2024 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05065541 | Sep 2021 → Jan 2024 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05099822 | Mar 2020 → Jul 2022 | — | Celgene Corporation | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07704840 | Jul 2026 → Jun 2027 expected | — | Alberto Esquenazi | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06808984 | Jun 2025 → Nov 2027 expected | Alzheimer disease | Celgene Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT06782490 | Jun 2025 → May 2027 expected | multiple sclerosis | Celgene Corporation | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986368 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06808984 ↗ |
| Known as | CC-97489 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05099822 ↗ |
| Action | Inhibit | “BMS-986368, a FAAH/MAGL Inhibitor” NCT06782490 ↗ |
| Route | Oral | “oral administration of single and multiple doses of CC-97489” NCT05065541 ↗ |
| Target | FAAH | “BMS-986368, a FAAH/MAGL Inhibitor” NCT06782490 ↗ |